A hormonal condition that affects millions of women worldwide has officially received a new name after years of debate among doctors, researchers and patient advocates.
Polycystic ovarian syndrome, widely known as PCOS, will now be called polyendocrine metabolic ovarian syndrome, or PMOS. Health experts say the shift reflects a broader understanding of a condition that extends far beyond ovarian cysts and fertility struggles.
The name change was announced this week following more than a decade of international collaboration involving medical organizations, researchers and patient advocacy groups. The decision was also published in The Lancet, one of the world’s leading medical journals.
Experts hope the updated terminology will improve awareness, reduce stigma and help patients receive earlier diagnoses and more effective care.
PMOS reflects a bigger health picture
For years, many doctors argued that the old name failed to capture the reality of the condition.
Despite the term ‘polycystic ovaries,’ not everyone diagnosed with the disorder develops ovarian cysts. The name also overlooked the hormonal, metabolic and mental health complications commonly linked to the condition.
PMOS is now being framed as a whole body endocrine disorder rather than only a reproductive issue.
Researchers say the condition can affect insulin regulation, cardiovascular health, fertility, sleep patterns, mental health and weight management. It has also been linked to increased risks of type 2 diabetes, heart disease and metabolic syndrome.
The condition impacts roughly 10% to 13% of women of reproductive age globally, according to the World Health Organization. Yet many cases still go undiagnosed for years because symptoms vary widely from person to person.
Doctors say those symptoms may include irregular menstrual cycles, acne, thinning hair, excess facial or body hair, infertility, anxiety, depression and difficulty managing weight.
Why experts pushed to change the name
Medical professionals involved in the renaming effort said the previous label contributed to confusion both inside and outside healthcare settings.
Some patients believed they needed visible ovarian cysts to receive a diagnosis. Others struggled to convince doctors their symptoms were connected because the condition appeared to involve multiple unrelated issues.
The updated name places greater emphasis on the endocrine system and metabolic complications tied to the disorder.
The ‘polyendocrine’ portion highlights the hormonal disruption involved, while ‘metabolic’ reflects the condition’s strong relationship with insulin resistance and long term cardiometabolic health.
Researchers believe the new terminology could also influence future studies and insurance coverage by encouraging healthcare systems to treat the condition as more than a gynecological issue.
PMOS treatment still focuses on symptoms
Although understanding of PMOS has evolved, treatment remains centered on symptom management rather than a cure.
Lifestyle changes are still considered the first line of treatment. Doctors often recommend balanced nutrition, regular exercise, improved sleep habits and reducing processed foods to help regulate hormones and insulin levels.
Some patients are prescribed medications such as Metformin to improve insulin sensitivity. Hormonal birth control is also commonly used to regulate menstrual cycles and manage acne or excess hair growth.
For patients trying to conceive, fertility treatments may help stimulate ovulation.
Healthcare providers say treatment plans often need to involve several specialties because the condition can affect so many parts of the body at once. Endocrinologists, gynecologists, dermatologists, nutritionists and mental health professionals may all play a role in care.
That fragmented care is one reason many advocates welcomed the new name. They hope PMOS encourages doctors to evaluate patients more holistically instead of focusing only on reproductive symptoms.
A larger conversation around women’s health
The renaming effort has also reignited conversations about how women’s health conditions are researched and funded.
Experts involved in the discussion for PMOS noted that disorders affecting women have historically received less research funding despite impacting millions globally. They believe the updated terminology could help attract broader scientific attention and improve public understanding.
Some researchers still argue the new name may continue evolving as science uncovers more about the condition’s causes and genetic links. Others believe PMOS already represents a major improvement because it better captures the disorder’s complexity.
For patients who spent years struggling to explain symptoms or secure treatment, many doctors say the new terminology represents more than semantics. It signals a shift in how medicine understands one of the most common but misunderstood hormonal disorders affecting women today.
